Neuro-Ophthalmic Consequences of Medications for Multiple Sclerosis: The Good, The Bad, The Ugly and The Unknown (abstract)

The landscape of therapies for multiple sclerosis (MS) is constantly shifting. Currently, there are 11 FDA approved agents for chronic disease treatment, multiple drugs in clinical trials for acute and chronic disease management and numerous compounds used for symptom control. Beyond treating patients who may be on these medications and in some cases prescribing these medications, neuroophthalmologists may be the evaluating physician for specific complications with neuro-ophthalmic symptoms and signs. Thus it is critically important that neuroophthalmologists stay abreast of new and emerging MS medications.